Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow
May 01 2024 - 2:48PM
Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader
and innovator in prostate care, announced today the release of new
features at the prestigious American Urological Association Annual
Meeting in San Antonio, TX. Koelis will be holding live and
interactive demos at its booth #951 from May 2nd to May 5th to
demonstrate its novel capacity integrating AI-enhanced prostate MRI
features into its exclusive Trinity platform.
The Koelis Trinity® system enables urologists to
perform 3D targeted “fusion biopsy” in prostate cancer. Trinity
integrates 3D ultrasound imaging with proprietary MRI-US fusion
image guidance that features the Company’s unique prostate motion
tracking software (OBT Fusion®). The compact Koelis Trinity® system
does not require interfaces with either external ultrasound
equipment or external sensors. The versatility of the Trinity
platform is enabling Koelis to lead the ongoing paradigm shift in
prostate cancer care to more accurate biopsy diagnoses and more
choices for less invasive treatments.
Koelis is releasing its new “Promap Contour”
software that has been developed in collaboration with companies
innovating in CAD and AI software, among which Deephealth (a wholly
owned subsidiary of Radnet), Siemens Healthineers, and others in
progress. The Promap Contour software will enable healthcare
providers to utilize their compatible CAD/AI solution to
automatically process Prostate contours and lesions on MRI that can
then be seamlessly transferred to the Koelis Trinity® platform
for 3D MRI/US fusion procedures.
Urologists and radiologists will be able to
collaborate to enhance workflow efficiencies along the prostate
cancer clinical pathway. The aim is to provide access to PACS/cloud
connectivity and automated prostate MRI segmentation to be readily
imported into the Koelis Trinity® platform. The Koelis Trinity®
system will utilize that imaging data to create a 3D
patient-specific prostate map for guidance of both diagnostic and
treatment procedures.
Antoine Leroy, PhD, Koelis founder and CEO,
declared: "Always responding and innovating to meet the needs of
urologists and their patients, Koelis is proud to enhance
connectivity and add an AI dimension to its products. We strongly
believe that promoting workflow efficiency with a solution like
DeepHealth’s, we can facilitate the adoption of Koelis fusion
biopsy as a new standard of care in the USA.”
Koelis technology is currently available in 50 countries
with over 500 systems in use in the USA, Europe and Asia. The
Koelis Trinity® platform has been utilized in 1 million patients
diagnosed with prostate cancer.
About Koelis
Headquartered in Grenoble, France, Koelis has
been a pioneer and leader of MRI-US fusion image guidance
technology since 2006. Featuring proprietary 3D ultrasound and
prostate motion tracking software (OBT Fusion®), the Koelis
Trinity® system facilitates more accurate biopsy diagnosis as well
as enabling “focal” prostate cancer treatment alternatives to
traditional “total” organ treatments such as surgical prostatectomy
and radiation. The Company’s commitment to minimally invasive
prostate cancer treatments includes a multi-center clinical
registry (“Violette”, NCT04582656) in Europe based on
Trinity-guided microwave ablation technology. Koelis has offices in
Grenoble (France), Princeton (NJ, USA), Saarbrücken (Germany) and
Singapore to serve in more than 50 countries. Learn more about
Koelis at www.koelis.com.
For Koelis media inquiries, please contact:
Thomas Martins PinheiroCommunications ManagerPhone: +33 (0)4 58
17 68 10Email: thomas.martins-pinheiro@koelis.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d8d0afda-6909-4bf4-9fbd-6b5ddf0a919a